Harnessing Innovative Platforms, Molecular & Cellular Assay Development & Screening Techniques to Explore Novel Protein Degradation Targets
Time: 11:30 am
day: Pre-Conference Workshop Day
Details:
Protein degradation has immense potential to drug the ‘undruggable’ – by eliminating disease causing proteins previously thought to be not addressable by classical therapeutic approaches. Extracellular proteins compose approximately 40% of the proteome, creating vast untapped potential until now…
Attend this Workshop to:
- Uncover the vast potential in unlocking extracellular targets for degradation via alternative pathways with pharmacokinetic/ pharmacodynamic insight
- Acquire the know-how and tools to develop biochemical assays for identifying and validating target binding outside the cell compared to intracellular proteins
- Leverage insight and lessons learned in three leading protein degradation companies enabling development of first-in-class and best-in-class targeted medicines
- EpiBiologics EpiTAC to degrade target proteins in the membrane and extracellularly
- Draupnir Bio’s platform to degrade proteins via small-molecule mediated lysosomal shuttling
- Dunad Therapeutics Claymor platform to degrade intracellular proteins
